Intelligence Platform

Patents

Browse 822 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11752137

Ophthalmic compositions for treating ocular Demodex using lotilaner formulations

Tarsus Pharmaceuticals, Inc. · Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11744816

Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of t

Esperion Therapeutics, Inc. · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11744800

Methods of use of emulsion formulations of an NK-1 receptor antagonist

Heron Therapeutics, Inc. · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11737991

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

TONIX PHARMA LIMITED · Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11737983

Storage stable sincalide formulations

MAIA PHARMACEUTICALS, INC. · Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11730793

Sustained release formulations using non-aqueous emulsions

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11730740

Laureth-4 containing topical formulations

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11732024

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11712475

Sustained delivery formulations of risperidone compound

Indivior UK Limited · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11707454

Topical roflumilast formulation having antifungal properties

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11701420

Parenteral norovirus vaccine formulations

Takeda Vaccines, Inc. · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11701421

Compositions and methods for stabilizing flaviviruses with improved formulations

Takeda Vaccines, Inc. · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11690827

Methods for treating ocular Demodex using lotilaner formulations

Tarsus Pharmaceuticals, Inc. · Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11690826

Methods for treating demodex blepharitis using lotilaner formulations

Tarsus Pharmaceuticals, Inc. · Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11692027

Antibody and protein therapeutic formulations and uses thereof

The Board of Regents of the University of Texas System · Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11690898

Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic for

BIOMARIN PHARMACEUTICAL INC. · Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11684614

Formulations of hydroxypyridonate actinide/lanthanide decorporation agents

The Regents of the University of California · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679078

Ophthalmic formulations and related methods

ETERNATEAR, INC. · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679079

Ophthalmic formulations and related methods

ETERNATEAR, INC. · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11673967

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11672863

Enhanced solubility drug-containing formulations

United Therapeutics Corporation · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11667702

Stable aqueous formulations of aflibercept

Coherus BioSciences, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11654124

Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives

AMNEAL PHARMACEUTICALS LLC · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11649207

Formulations of T-type calcium channel modulators and methods of use thereof

PRAXIS PRECISION MEDICINES, INC. · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted